Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Cipher Pharmaceuticals Inc. (CPH.TO)
Mississauga, ON, CA
Cipher Pharmaceuticals Inc., founded in 2000 and based in Oakville, Canada, operates as a specialized pharmaceutical enterprise. The company markets a diverse portfolio of commercial therapeutic solutions. These include Epuris (CIP-ISOTRETINOIN), formulated for severe acne; Ozenoxacin, targeting impetigo in both adult and pediatric patients; Actikerall, prescribed for palpable or moderately thick hyperkeratotic actinic keratosis; Vaniqa, a topical cream designed to mitigate unwanted facial hair growth in women; BRINAVESS, utilized for restoring sinus rhythm in adults; and AGGRASTAT, an intravenous anti-platelet medication. Beyond its directly marketed offerings, Cipher's portfolio encompasses various licensed products, such as CIP-Isotretinoin; Lipofen (CIP-Fenofibrate), used in the management of hyperlipidemia, a lipid metabolism disorder; and Conzip/Durela (CIP-Tramadol), indicated for the relief of moderate to moderately severe pain. Looking to the future, Cipher maintains a robust developmental pipeline, which includes Trevyent, a vasodilatory prostacyclin analogue aimed at treating pulmonary arterial hypertension; CF-101, under investigation for severe plaque psoriasis and rheumatoid arthritis; MOB-015, a topical terbinafine formulation for onychomycosis; and DTR-001, a novel cream for tattoo removal.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -7.55% | +2.13% | -2.14% | +28.52% | +34.39% | +21.18% | +38.26% | +421.43% | +1,303.85% | +137.63% | +607.36% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 2 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+53.9% ★ Q1'26: +2.3% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+127.7% ★ Q1'26: +140.0% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+60.9% Q1'26: +36.2% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+32.7% ★ Q1'26: +44.7% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+13.6% ★ Q1'26: +17.4% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+5.8% Q1'26: -1.5% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×0.33× ★ Q1'26: 0.01× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 3 Rev. Ana. 3 EPS Ana. |
Dec 2027 2 Rev. Ana. 2 EPS Ana. |
Dec 2028 2 Rev. Ana. 2 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
Dec 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
34.41M
est: 47.59M (-27.7%)
|
40.74M
est: 54.50M (-25.2%)
|
40.32M
est: 44.88M (-10.2%)
|
22.75M
est: 31.63M (-28.1%)
|
22.45M
est: 28.60M (-21.5%)
|
21.61M
est: 26.03M (-17.0%)
|
21.94M
est: 27.92M (-21.4%)
|
20.68M
est: 29.04M (-28.8%)
|
21.16M
est: 16.21M (+30.6%)
|
33.36M
est: 33.03M (+1.0%)
|
51.33M
est: 50.87M (+0.9%)
|
53.25M
50.37M – 56.34M
+4.7% YoY
|
65.12M
62.07M – 68.18M
+22.3% YoY
|
67.64M
64.25M – 71.15M
+3.9% YoY
|
70.17M
66.65M – 73.81M
+3.7% YoY
|
71.15M
67.59M – 74.85M
+1.4% YoY
|
| EBITDA |
7.19M
est: 25.94M (-72.3%)
|
12.66M
est: 29.71M (-57.4%)
|
26.03M
est: 24.47M (+6.4%)
|
6.16M
est: 17.24M (-64.3%)
|
12.87M
est: 15.59M (-17.4%)
|
13.40M
est: 14.19M (-5.6%)
|
13.66M
est: 15.22M (-10.2%)
|
12.04M
est: 15.83M (-23.9%)
|
11.53M
est: 7.89M (+46.2%)
|
11.87M
est: 16.07M (-26.2%)
|
16.80M
est: 24.75M (-32.1%)
|
25.91M
24.51M – 27.41M
+4.7% YoY
|
31.68M
30.20M – 33.17M
+22.3% YoY
|
32.91M
31.26M – 34.61M
+3.9% YoY
|
34.14M
32.43M – 35.91M
+3.7% YoY
|
34.62M
32.88M – 36.41M
+1.4% YoY
|
| EBIT |
2.68M
est: 22.95M (-88.3%)
|
13.49M
est: 26.28M (-48.7%)
|
19.39M
est: 21.65M (-10.4%)
|
4.03M
est: 15.25M (-73.6%)
|
11.50M
est: 13.79M (-16.6%)
|
12.16M
est: 12.55M (-3.1%)
|
13.06M
est: 13.46M (-3.0%)
|
11.05M
est: 14.01M (-21.1%)
|
10.30M
est: 7.05M (+46.2%)
|
7.85M
est: 14.37M (-45.4%)
|
16.80M
est: 22.12M (-24.0%)
|
23.16M
21.91M – 24.50M
+4.7% YoY
|
28.32M
26.99M – 29.65M
+22.3% YoY
|
29.41M
27.94M – 30.94M
+3.9% YoY
|
30.51M
28.99M – 32.10M
+3.7% YoY
|
30.94M
29.39M – 32.55M
+1.4% YoY
|
| Net Income |
1.77M
est: -689.7K (+356.5%)
|
-39.15M
est: -18.64M (-110.0%)
|
4.40M
est: 10.00M (-56.0%)
|
543.0K
est: 3.59M (-84.9%)
|
3.24M
est: 2.75M (+17.8%)
|
4.55M
est: 6.05M (-24.8%)
|
7.76M
est: 6.82M (+13.7%)
|
26.64M
est: 8.67M (+207.1%)
|
20.38M
est: 16.53M (+23.3%)
|
11.55M
est: 12.92M (-10.7%)
|
27.81M
est: 18.02M (+54.3%)
|
20.44M
16.92M – 23.95M
+13.4% YoY
|
21.78M
18.24M – 25.32M
+6.6% YoY
|
23.18M
21.22M – 25.14M
+6.4% YoY
|
26.49M
24.77M – 28.28M
+14.3% YoY
|
27.77M
25.96M – 29.64M
+4.8% YoY
|
| SGA |
25.41M
est: 12.93M (+96.5%)
|
38.20M
est: 14.81M (+158.0%)
|
12.78M
est: 12.20M (+4.8%)
|
14.74M
est: 8.59M (+71.5%)
|
7.65M
est: 7.77M (-1.6%)
|
6.26M
est: 7.07M (-11.5%)
|
5.11M
est: 7.59M (-32.6%)
|
4.40M
est: 7.89M (-44.2%)
|
5.43M
est: 4.54M (+19.6%)
|
12.24M
est: 9.24M (+32.4%)
|
16.95M
est: 14.23M (+19.1%)
|
14.90M
14.10M – 15.76M
+4.7% YoY
|
18.22M
17.37M – 19.08M
+22.3% YoY
|
18.93M
17.98M – 19.91M
+3.9% YoY
|
19.63M
18.65M – 20.65M
+3.7% YoY
|
19.91M
18.91M – 20.94M
+1.4% YoY
|
| EPS |
0.07
est: -0.03 (+349.3%)
|
-1.49
est: -0.76 (-96.3%)
|
0.16
est: 0.41 (-60.7%)
|
0.02
est: 0.15 (-86.1%)
|
0.12
est: 0.11 (+7.1%)
|
0.17
est: 0.25 (-30.9%)
|
0.29
est: 0.28 (+4.4%)
|
1.06
est: 0.35 (+199.8%)
|
0.80
est: 0.68 (+18.2%)
|
0.47
est: 0.50 (-5.4%)
|
1.09
est: 0.69 (+58.0%)
|
0.76
0.65 – 0.92
+10.3% YoY
|
0.84
0.70 – 0.97
+10.1% YoY
|
0.89
0.82 – 0.97
+6.4% YoY
|
1.02
0.95 – 1.09
+14.3% YoY
|
1.07
1.00 – 1.14
+4.8% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-08 | A+ | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-07 | A+ | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-06 | A+ | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-05 | A+ | 5/5 | 5/5 | 5/5 | 5/5 | 3/5 | 4/5 | 3/5 |
| 2026-05-04 | A+ | 5/5 | 5/5 | 5/5 | 5/5 | 3/5 | 4/5 | 3/5 |
| 2026-05-01 | A+ | 5/5 | 5/5 | 5/5 | 5/5 | 3/5 | 4/5 | 3/5 |
| 2026-04-30 | A+ | 5/5 | 5/5 | 5/5 | 5/5 | 3/5 | 4/5 | 3/5 |
| 2026-04-29 | A+ | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 4/5 | 3/5 |
| 2026-04-28 | A+ | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 4/5 | 3/5 |
| 2026-04-27 | A+ | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 4/5 | 3/5 |
| 2026-04-24 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-23 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-22 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-21 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-20 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-17 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-16 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Dimensional - International Small Cap ETF DFIS | 0.00% | 147.0K | 0.39% |
| 2 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 144.5K | 0.28% |
| 3 | Dimensional - International Core Equity 2 ETF DFIC | 0.00% | 78.1K | 0.22% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Bryan Jacobs | President | 666.7K | male |
| Craig J. Mull | Interim Chief Executive Officer & Chairman of the Board | 350.0K | male |
| Ryan Mailling | Chief Financial Officer | 287.3K | male |
| Emilio Presti | Director of Sales & Marketing | — | male |
| Shengnan Guo | Corporate Controller | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for CPH.TO
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
